StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Karyopharm Therapeutics (KPTI)

Thu, 18 Jun 2026 06:48:48 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $13.00 price target on Karyopharm Therapeutics (NASDAQ: KPTI).

The analyst commented: "At ASCO and EHA, Karyopharm presented results from the Phase 3 SENTRY trial evaluating Xpovio (selinexor) 60mg + Jakafi (ruxolitinib) vs. Jakafi in JAKi-naïve myelofibrosis (MF) patients; the co-primary endpoints (tested sequentially) are spleen volume reduction of 35% or more (SVR35) at week 24 and absolute mean change in total symptom score (Abs-TSS) from baseline to week 24. As seen in the oral presentations, Xpovio 60mg + Jakafi reduced spleen volume by >35% at week 24 in 49.8% vs 28%

Karyopharm Therapeutics (KPTI) Reiterated at Overweight by Cantor Fitzgerald

Tue, 09 Jun 2026 07:18:00 -0400

Cantor Fitzgerald analyst Yanni Souroutzidis reiterated an Overweight rating on Karyopharm Therapeutics (NASDAQ: KPTI).

The analyst commented, "we had the opportunity to sit down with management to focus on selinexor's opportunity within endometrial cancer maintenance. The discussion touched on the unmet need, selinexor's mechanism-of-action (MoA), how existing SIENDO data de-risks the ongoing Ph 3 XPORT-EC-042 (XPORT) study, and the team's expectations for the trial, as well as how they feel positioned to continue to pursue both MF and EC opportunities. Recall, Karyopharm is developing selinexor, a weekly oral nuclear export (XPO1) inhibitor currently approved for multiple myeloma and in development for

Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: T. Rowe Price Investment Management, Inc.

Fri, 05 Jun 2026 11:43:00 -0400

si-local-file:///var/storage/secattach/20260605/26609719.html

Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: T. Rowe Price Investment Management, Inc.

Fri, 05 Jun 2026 11:43:00 -0400

si-local-file:///var/storage/secattach/20260605/26609719.html

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

Wed, 03 Jun 2026 16:15:00 -0400

NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will participate in a virtual fireside chat hosted by Cantor on June 8, 2026 at 12:00 p.m. ET. The event will feature the Company's senior management team and Robert Coleman, MD, FACOG, FACS, a globally recognized gynecologist oncologist and Principal Investigator of the Phase 3 XPORT-EC-042 trial.

Institutional investors interested in attending the live event should contact their Cantor representative. A replay of this event will be available

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

Wed, 03 Jun 2026 16:15:00 -0400

Institutional investors interested in attending the live event should contact their Cantor representative. A replay of this event will be available

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

Wed, 03 Jun 2026 16:15:00 -0400

Institutional investors interested in attending the live event should contact their Cantor representative. A replay of this event will be available

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

Wed, 03 Jun 2026 16:15:00 -0400

Institutional investors interested in attending the live event should contact their Cantor representative. A replay of this event will be available

Karyopharm cancer trial selected for late-breaking presentation at EHA

Tue, 02 Jun 2026 10:03:28 -0400

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) announced that its Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis was selected for a late-breaking oral presentation at the 2026 European Hematology Association Congress, scheduled for June 11-14 in Stockholm, Sweden.

The presentation was chosen by EHA's Scientific Program Committee as one of six abstracts for the Late-Breaking Oral Session on June 14. The SENTRY trial is a randomized, double-blind, placebo-controlled study of 60 mg selinexor combined with ruxolitinib in 353 myelofibrosis patients with platelet counts above 100 x 10⁹/L.

The abstract reports that the combination therapy enabled rapid, sustained spleen volume reductions and

Karyopharm cancer trial selected for late-breaking presentation at EHA

Tue, 02 Jun 2026 10:03:28 -0400

The abstract reports that the combination therapy enabled rapid, sustained spleen volume reductions and

Karyopharm cancer trial selected for late-breaking presentation at EHA

Tue, 02 Jun 2026 10:03:28 -0400

The abstract reports that the combination therapy enabled rapid, sustained spleen volume reductions and

Karyopharm cancer trial selected for late-breaking presentation at EHA

Tue, 02 Jun 2026 10:03:28 -0400

The abstract reports that the combination therapy enabled rapid, sustained spleen volume reductions and

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

Tue, 02 Jun 2026 10:02:00 -0400

– New Data will Highlight a Post-Hoc Analysis from Phase 1 Portion of SENTRY Trial that Indicates Achievement of SVR35 with Selinexor plus Ruxolitinib May Predict Overall Survival –